CD5 and CD43 expression are associate with poor prognosis in DLBCL patients

Affiliations

Huang Hui: Department of Integration of Chinese and Western Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, Beijing 100142, P. R China
Li Zhandong: Department of Integration of Chinese and Western Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, Beijing 100142, P. R China
Huang Chuansheng: Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Rao Jun: Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Xie Qin: Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Cui Wenhao: Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan
Tou Fangfang: Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Zheng Zhi: Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China

Abstract

To investigate the expression and clinical significance of CD5 and CD43 in diffuse large B cell lymphoma (DLBCL) (unspecified).